- About Us
Dr. Alfred Botchway is Founder and President of Xenometrics, LLC a nonclinical contract research laboratory which focuses on assessing the safety profile of pharmaceutical and agrochemical products. Alfred has numerous years of experience spanning academic research, a major pharmaceutical company and a contract laboratory, consequently retaining considerable insight into drug and/or chemical development. Alfred’s experience includes developing cost effective methods, managing multi-million dollar budgets, and extensive research in safety pharmacology with particular emphasis on arrhythmogenic activities. Dr. Alfred Botchway served as the President of the International Safety Pharmacology Society, after having been on the Board of Directors for over 5 years. In addition to his scientific endeavors, he also serves on the State of Kansas’s Council of Economic Advisors. Alfred graduated from Pipeline (an Entrepreneurial Immersion Program), and was elected the first President of the Alumni and served on the Pipeline Board of Directors for numerous years. After Xenometrics was acquired by Citoxlab (a global nonclinical contract research laboratory with headquarters in France), Alfred remained with Citoxlab and is now part of the Executive team furthering the growth of Citoxlab’s Kansas City site as well as assisting with strategic planning for seven other global sites. Dr. Alfred Botchway is an investor in his own right and remains an active angel investor.
Alfred holds a BSc and an MSc in Biomedical Science from the University of Kingston, Surrey, UK and the North East College of Technology, Surrey, UK, respectively. By virtue of his masters (hematology major), he developed a keen interest in cardiovascular physiology. Subsequent to a special interest and research in electrophysiological changes associated with regression of left ventricular hypertrophy, Alfred was awarded a Ph.D. from the Imperial College of Science, Technology and Medicine, London, UK.